The testing of NGM282 for 12 weeks in patients with Primary Sclerosing Cholangitis (PSC)
A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EV ...
Product Name: NGM282 INN or Proposed INN: engineeredrecombinanthumanFGF19 Other descriptive name: rec-h-FGF19 Product Name: NGM282 INN or Proposed INN: engineeredrecombinanthumanFGF19 Other descriptive name: rec-h-FGF19Product Name: NGM282 INN or Proposed INN: engineeredrecombinanthumanFGF19 Other descriptive name: r ...
The testing of NGM282 for 12 weeks in patients with Primary Sclerosing Cholangitis (PSC)
A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EV ...
Product Name: NGM282 INN or Proposed INN: engineeredrecombinanthumanFGF19 Other descriptive name: rec-h-FGF19 Product Name: NGM282 INN or Proposed INN: engineeredrecombinanthumanFGF19 Other descriptive name: rec-h-FGF19Product Name: NGM282 INN or Proposed INN: engineeredrecombinanthumanFGF19 Other descriptive name: r ...